Over the next few weeks, as your body adjusts to the higher doses, you may begin to experience more noticeable weight loss and further reduction in appetite
The amount of weight varies from patient to patient
Multi-factorial risk scoring incorporates patient factors, medication characteristics, and procedural requirements to stratify patients into low, moderate, and high-risk categories [54]
The flow of subjects through the trial is presented in Fig
N Engl J Med 390:13941407 Deanfield JE (2024) Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure: a pre-specified analysis from the select tria.l Euro Soc Cardiol Heart Fail Congress Spertus JA, Jones PG, Sandhu AT, Arnold SV (2020) Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review
10.1196/annals.1297.059 Ann N Y Acad Sci